AdCMVmCD40L

AdCMVmCD40L is an adenoviral vector-based gene therapy encoding the **CD40 ligand (CD40L)** gene, under the control of the cytomegalovirus (CMV) promoter, typically of mouse (murine) origin. It is designed to transduce tumor or host tissue cells to express CD40L, leading to enhanced activation of CD40 signaling pathways. This results in the stimulation of both **cellular and humoral immunity**, notably increasing cytotoxic CD8+ T cell function and natural killer (NK) cell activity, as well as inducing tumor-specific antibodies. The primary reported indication is **cancer immunogene therapy**, particularly for solid tumors such as hepatocellular carcinoma (HCC), utilizing mechanisms such as immune cell activation, apoptosis induction in tumor cells, and modulation of the tumor microenvironment. The therapy has demonstrated persistent tumor regression and protective antitumor immunity in animal models, without significant systemic toxicity.

Other names

adenovirus vector encoding mouse CD40 ligandAd-mCD40LAd-mCD-40LAd-mCD 40LAdenovirus-mediated CD40L gene therapy